Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2014-04-16 M&A Activity
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
M&A Activity Classification · 99% confidence The document explicitly announces that 'BIOALLIANCE PHARMA AND TOPOTARGET ENTER INTO MERGER AGREEMENT'. It details the terms of the merger, including share exchange ratios, expected completion dates, and governance changes. This subject matter directly relates to a significant corporate transaction involving a merger proposal. According to the definitions, the code for M&A Activity (merger proposals or takeover bids) is TAR. The document is a detailed announcement, not a short notice of publication, so RPA/RNS is not the primary classification.
2014-04-16 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
M&A Activity Classification · 99% confidence The document text is a press release announcing a definitive agreement for a merger (fusion) between two pharmaceutical companies, BioAlliance Pharma and Topotarget. It details the exchange ratio (2 new BioAlliance shares for 27 Topotarget shares), the resulting ownership structure (2/3 vs 1/3), the strategic rationale (creating a major player in orphan oncology drugs), key product pipelines (Belinostat, Livatag®, Validive®), and the expected timeline, including dates for shareholder meetings and the expected closing. This type of announcement, detailing a significant corporate transaction like a merger or takeover bid, directly corresponds to the definition of M&A Activity (TAR). It is not a standard periodic report (10-K, IR) or a simple announcement of a report (RPA).
2014-04-16 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated April 14, 2014, announcing a positive Data Safety and Monitoring Board (DSMB) recommendation to continue a Phase III clinical trial (ReLive) for the drug Livatag®. This type of announcement, detailing progress in clinical development, safety data assessment, and enrollment status, is typically classified as a general corporate update or news release. It does not fit the specific definitions for financial reports (10-K, IR, ER), governance documents (CGR, DEF 14A), or capital actions (CAP, SHA). Since it is a specific operational update that doesn't fit the other specialized categories, the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings), as it is a formal communication to the market about a significant operational event.
2014-04-14 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated April 14, 2014, announcing a positive recommendation from the independent Data Safety and Monitoring Board (DSMB) for the continuation of the Phase III clinical trial (ReLive) for the drug Livatag® in liver cancer. This announcement details clinical trial progress, patient recruitment status, and future timelines. It is not a full Annual Report (10-K), an official Audit Report (AR), a formal Earnings Release (ER), or a transcript (CT). It is an update regarding ongoing business/development activities, specifically clinical trial progress, which often falls under general regulatory announcements or investor relations updates. Since it is a specific announcement about a development milestone rather than a standard financial report, and it doesn't fit perfectly into the other specific categories (like M&A, Capital Change, or Dividend), it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format detailing operational progress, RNS is the most appropriate general category for non-standard, material operational updates.
2014-04-14 French
Document availability communications / Preparatory documents for the general meeting
AGM Information Classification · 98% confidence The document explicitly announces that the company held its 'Shareholders' meeting' and adopted all resolutions. It details the re-election of specific directors and provides a link to where the 'Voting results of the Combined Shareholders Meeting' can be found. This content is directly related to the proceedings and outcomes of a general meeting of shareholders. While it mentions the approval of resolutions, the primary focus is on the meeting itself and the confirmation of board members, which aligns best with the scope of an Annual General Meeting (AGM) announcement or related material. Since the document is an announcement summarizing the meeting's outcome rather than the formal voting results document (DVA) or a proxy solicitation (PSI), AGM-R is the most appropriate classification for materials shared during or immediately following the AGM.
2014-04-08 English
Communiqués de mise à disposition de documents / Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 98% confidence The document is titled "Assemblée Générale Mixte de BioAlliance Pharma : Approbation de toutes les résolutions" (Mixed General Meeting of BioAlliance Pharma: Approval of all resolutions). It explicitly discusses the meeting of shareholders, the renewal of board mandates, and the results of the votes, stating that the results are available on the website. This content directly relates to the proceedings and outcomes of a shareholder meeting. The most appropriate category is AGM Information (AGM-R), as it details the events and outcomes of the Annual General Meeting.
2014-04-08 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.